The effect of SNPs in CYP450 in chloroquine/primaquine Plasmodium vivax malaria treatment-Reference-Cited by-同舟云学术

The effect of SNPs in CYP450 in chloroquine/primaquine Plasmodium vivax malaria treatment

Published:2016-11 Issue:17 Volume:17 Page:1903-1911
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Sortica Vinicius A¹,Lindenau Juliana D¹,Cunha Maristela G²,Ohnishi Maria DO³,Ventura Ana Maria R³,Ribeiro-dos-Santos Ândrea KC⁴,Santos Sidney EB⁴,Guimarães Luciano SP⁵,Hutz Mara H¹

Affiliation:

1. Departamento de Genética, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

2. Laboratório de Microbiologia e Imunologia, Universidade Federal do Pará, Belém, PA, Brazil

3. Programa de Ensaios Clínicos em Malária, Instituto Evandro Chagas, Sistema de Vigilância Sanitária, Ministério da Saúde, Ananindeua, PA, Brazil

4. Laboratório de Genética Humana e Médica, Universidade Federal do Pará, Belém, PA, Brazil

5. Unidade de Bioestatística, Grupo de Pesquisa e Pós Graduação, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

Abstract

Background: Chloroquine/primaquine is the current therapy to eliminate Plasmodium vivax infection in the Amazon region. Aims: This study investigates CYP1A2, CYP2C8, CYP2C9, CYP3A4 and CYP3A5 genetic polymorphisms influence on cloroquine/primaquine treatment. Patients & methods: Generalized estimating equations analyses were performed to determine the genetic influence in parasitemia and/or gametocytemia clearance over treatment time in 164 patients. Results: An effect of CYP2C8 low-activity alleles on treatment was observed (p = 0.01). From baseline to first day of treatment, wild-type individuals achieved greater reduction of gametocytes than low-activity allele carriers. CYP2C9 and CYP3A5 genes showed a trend for gametocytemia and parasitemia clearance rates. Conclusion: Future studies should be performed to access the extent of CYP2C8, CYP2C9 and CYP3A5 gene polymorphisms influence on cloroquine/primaquine treatment.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2016-0131

Reference40 articles.

1. Pharmacogenetics – five decades of therapeutic lessons from genetic diversity

2. Challenges for malaria elimination in Brazil

3. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism-a panel study.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenomics of chloroquine and hydroxychloroquine: current evidence and future implications;Pharmacogenomics;2023-10

2. Biological Activities of Morita-Baylis-Hillman Adducts (MBHA);Mini-Reviews in Medicinal Chemistry;2023-09

3. Pharmacogenomic variation in the Malagasy population: implications for the antimalarial drug primaquine metabolism;Pharmacogenomics;2023-07

4. Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles;International Journal of Molecular Sciences;2023-02-08

5. Insights and Current Perspectives on Pharmacogenomics of Antimalarial Drugs;2022-09-08